GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » D&D Pharmatech Inc (XKRX:347850) » Definitions » EV-to-EBITDA

D&D Pharmatech (XKRX:347850) EV-to-EBITDA : (As of Jun. 21, 2024)


View and export this data going back to 2024. Start your Free Trial

What is D&D Pharmatech EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, D&D Pharmatech's enterprise value is ₩282,425 Mil. D&D Pharmatech does not have enough years/quarters to calculate its EBITDA for the trailing twelve months (TTM) ended in Dec. 2023. Therefore, GuruFocus does not calculate D&D Pharmatech's EV-to-EBITDA at this moment.

The historical rank and industry rank for D&D Pharmatech's EV-to-EBITDA or its related term are showing as below:

XKRX:347850' s EV-to-EBITDA Range Over the Past 10 Years
Min: 25.19   Med: 28.77   Max: 198.35
Current: 195.11

During the past 6 years, the highest EV-to-EBITDA of D&D Pharmatech was 198.35. The lowest was 25.19. And the median was 28.77.

XKRX:347850's EV-to-EBITDA is ranked worse than
96.97% of 462 companies
in the Biotechnology industry
Industry Median: 8.865 vs XKRX:347850: 195.11

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-21), D&D Pharmatech's stock price is ₩27800.00. D&D Pharmatech does not have enough years/quarters to calculate its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023. Therefore, GuruFocus does not calculate D&D Pharmatech's PE Ratio (TTM) at this moment.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).

D&D Pharmatech EV-to-EBITDA Historical Data

The historical data trend for D&D Pharmatech's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

D&D Pharmatech EV-to-EBITDA Chart

D&D Pharmatech Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial - - - - -

D&D Pharmatech Quarterly Data
Dec22 Sep23 Dec23
EV-to-EBITDA - - -

Competitive Comparison of D&D Pharmatech's EV-to-EBITDA

For the Biotechnology subindustry, D&D Pharmatech's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

D&D Pharmatech's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, D&D Pharmatech's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where D&D Pharmatech's EV-to-EBITDA falls into.


D&D Pharmatech EV-to-EBITDA Calculation

D&D Pharmatech's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=282424.900/
=

D&D Pharmatech  (XKRX:347850) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

D&D Pharmatech's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=27800.00/
=

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?

D&D Pharmatech EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of D&D Pharmatech's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

D&D Pharmatech (XKRX:347850) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » D&D Pharmatech Inc (XKRX:347850) » Definitions » EV-to-EBITDA
Comparable Companies
Traded in Other Exchanges
N/A
Address
4th floor, 24, Pangyo-ro 255beon-gil, Bundang-gu, Gyeonggi-do, Sampyeong-dong, I&C Building, Seongnam-si, KOR
Website
http://www.ddpharmatech.com
D&D Pharmatech Inc is a company that comprises of experts in the field of bio-new drug research and development and technology commercialization, including basic scientists in the pharmaceutical biofield, manufacturing quality control (CMC) experts, and clinical development and technology transfer experts. Other business areas include the development of positron emission tomography (PET) imaging biomarkers conducted by Precision Molecular Inc. a 100% subsidiary, and single-cell sequencing related to degenerative brain diseases conducted by Valted Seq, Inc. The company utilizes drug delivery technologies such as PEGylation technology, which helps extend the administration interval using PEG and various chemicals, and platform technology that converts injectable drugs into oral preparations.

D&D Pharmatech (XKRX:347850) Headlines

No Headlines